ARTG Name
Suspended from ARTG - MEDI CHOICE HEARTBURN & ACID INDIGESTION ranitidine hydrochloride 167.5mg tablet blister pack
Product name
MEDI CHOICE HEARTBURN & ACID INDIGESTION ranitidine hydrochloride 167.5mg tablet blister pack
ARTG Date
Registration Type
Medicine
Therapeutic good type
Medicines
Ingredients
ranitidine hydrochloride
Licence category
RE
Licence status
A
Summary
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 28/01/2020
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29/01/2021
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29/07/2021
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29/01/2022
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29/01/2023
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29-07-2023
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29/01/2024
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29/07/2024
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29/01/2025
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29/07/2025
-
2023-24Annual charge exemptionExempt from annual charge in 2023-24 due to Nova Pharmaceuticals Australasia Pty Ltd declaring $0 turnover in that period.